Annual EBITDA
-$64.18 M
+$18.33 M+22.21%
December 31, 2023
Summary
- As of February 7, 2025, APLT annual EBITDA is -$64.18 million, with the most recent change of +$18.33 million (+22.21%) on December 31, 2023.
- During the last 3 years, APLT annual EBITDA has risen by +$29.91 million (+31.78%).
- APLT annual EBITDA is now -1397.81% below its all-time high of -$4.29 million, reached on December 31, 2017.
Performance
APLT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$29.64 M
-$9.32 M-45.88%
September 30, 2024
Summary
- As of February 7, 2025, APLT quarterly EBITDA is -$29.64 million, with the most recent change of -$9.32 million (-45.88%) on September 30, 2024.
- Over the past year, APLT quarterly EBITDA has dropped by -$14.26 million (-92.75%).
- APLT quarterly EBITDA is now -1486.67% below its all-time high of -$1.87 million, reached on March 31, 2018.
Performance
APLT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$91.93 M
-$14.26 M-18.36%
September 30, 2024
Summary
- As of February 7, 2025, APLT TTM EBITDA is -$91.93 million, with the most recent change of -$14.26 million (-18.36%) on September 30, 2024.
- Over the past year, APLT TTM EBITDA has dropped by -$29.89 million (-48.18%).
- APLT TTM EBITDA is now -4821.41% below its all-time high of -$1.87 million, reached on March 31, 2018.
Performance
APLT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
APLT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.2% | -92.8% | -48.2% |
| 3 y3 years | +31.8% | -4.6% | +9.7% |
| 5 y5 years | -374.8% | -68.0% | -101.8% |
APLT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +39.0% | -175.9% | at low | -48.2% | +12.6% |
| 5 y | 5-year | -40.9% | +39.0% | -175.9% | +0.8% | -101.8% | +13.1% |
| alltime | all time | -1397.8% | +39.0% | -1486.7% | +0.8% | -4821.4% | +13.1% |
Applied Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.64 M(+45.9%) | -$91.93 M(+18.4%) |
| Jun 2024 | - | -$20.32 M(-3.1%) | -$77.67 M(+4.4%) |
| Mar 2024 | - | -$20.97 M(-0.1%) | -$74.41 M(+15.9%) |
| Dec 2023 | -$64.18 M(-22.2%) | -$21.00 M(+36.6%) | -$64.18 M(+3.5%) |
| Sep 2023 | - | -$15.38 M(-9.9%) | -$62.04 M(-5.9%) |
| Jun 2023 | - | -$17.06 M(+58.8%) | -$65.91 M(-6.2%) |
| Mar 2023 | - | -$10.74 M(-43.0%) | -$70.26 M(-14.8%) |
| Dec 2022 | -$82.51 M(-21.6%) | -$18.86 M(-2.0%) | -$82.51 M(-9.0%) |
| Sep 2022 | - | -$19.25 M(-10.1%) | -$90.66 M(-9.1%) |
| Jun 2022 | - | -$21.41 M(-6.9%) | -$99.74 M(-4.2%) |
| Mar 2022 | - | -$22.99 M(-14.9%) | -$104.10 M(-1.1%) |
| Dec 2021 | -$105.20 M | -$27.01 M(-4.6%) | -$105.20 M(+3.3%) |
| Sep 2021 | - | -$28.32 M(+9.9%) | -$101.84 M(-1.5%) |
| Jun 2021 | - | -$25.77 M(+6.9%) | -$103.39 M(-2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$24.10 M(+1.9%) | -$105.80 M(+12.5%) |
| Dec 2020 | -$94.09 M(+106.5%) | -$23.65 M(-20.8%) | -$94.08 M(+6.8%) |
| Sep 2020 | - | -$29.87 M(+6.0%) | -$88.08 M(+27.7%) |
| Jun 2020 | - | -$28.19 M(+127.8%) | -$68.95 M(+40.1%) |
| Mar 2020 | - | -$12.37 M(-29.9%) | -$49.20 M(+8.0%) |
| Dec 2019 | -$45.56 M(+237.0%) | -$17.65 M(+64.2%) | -$45.56 M(+34.4%) |
| Sep 2019 | - | -$10.75 M(+27.4%) | -$33.90 M(+28.0%) |
| Jun 2019 | - | -$8.44 M(-3.3%) | -$26.48 M(+29.9%) |
| Mar 2019 | - | -$8.73 M(+45.8%) | -$20.38 M(+50.8%) |
| Dec 2018 | -$13.52 M(+215.5%) | -$5.99 M(+80.2%) | -$13.52 M(+79.5%) |
| Sep 2018 | - | -$3.32 M(+42.2%) | -$7.53 M(+79.0%) |
| Jun 2018 | - | -$2.34 M(+25.1%) | -$4.21 M(+125.1%) |
| Mar 2018 | - | -$1.87 M | -$1.87 M |
| Dec 2017 | -$4.29 M | - | - |
FAQ
- What is Applied Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Applied Therapeutics?
- What is Applied Therapeutics annual EBITDA year-on-year change?
- What is Applied Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Applied Therapeutics?
- What is Applied Therapeutics quarterly EBITDA year-on-year change?
- What is Applied Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Applied Therapeutics?
- What is Applied Therapeutics TTM EBITDA year-on-year change?
What is Applied Therapeutics annual EBITDA?
The current annual EBITDA of APLT is -$64.18 M
What is the all time high annual EBITDA for Applied Therapeutics?
Applied Therapeutics all-time high annual EBITDA is -$4.29 M
What is Applied Therapeutics annual EBITDA year-on-year change?
Over the past year, APLT annual EBITDA has changed by +$18.33 M (+22.21%)
What is Applied Therapeutics quarterly EBITDA?
The current quarterly EBITDA of APLT is -$29.64 M
What is the all time high quarterly EBITDA for Applied Therapeutics?
Applied Therapeutics all-time high quarterly EBITDA is -$1.87 M
What is Applied Therapeutics quarterly EBITDA year-on-year change?
Over the past year, APLT quarterly EBITDA has changed by -$14.26 M (-92.75%)
What is Applied Therapeutics TTM EBITDA?
The current TTM EBITDA of APLT is -$91.93 M
What is the all time high TTM EBITDA for Applied Therapeutics?
Applied Therapeutics all-time high TTM EBITDA is -$1.87 M
What is Applied Therapeutics TTM EBITDA year-on-year change?
Over the past year, APLT TTM EBITDA has changed by -$29.89 M (-48.18%)